Prostaglandin F receptor-alternative Prostaglandin F receptor heterodimer (FP-altFP) (FP-altFP)

The FP-altFP heterodimer is a specialized receptor complex composed of the canonical Prostaglandin F (FP) receptor and its alternative splice variant, altFP [Liang et al., 2008, British Journal of Pharmacology]. This complex is widely recognized as the putative "prostamide receptor," specifically mediating the effects of prostaglandin-ethanolamides like bimatoprost [Woodward et al., 2012, British Journal of Pharmacology]. Unlike the native FP receptor which primarily binds prostaglandin F2-alpha, the heterodimer exhibits a unique pharmacological profile that is sensitive to amide-containing lipids [Davies et al., 2002, Journal of Biological Chemistry]. Its primary biological role is the regulation of intraocular pressure by facilitating the uveoscleral outflow of aqueous humor from the eye [Woodward et al., 2003, Survey of Ophthalmology]. In clinical practice, this target is the focus of therapies for open-angle glaucoma and ocular hypertension [NIH, StatPearls: Glaucoma Medications]. Drugs targeting this complex, such as bimatoprost, are highly effective but can cause side effects like increased eyelash growth and iris color changes [PubChem, Bimatoprost]. The existence of this heterodimer explains why certain prostamides remain active in tissues where traditional FP receptor antagonists fail to block their effects [Liang et al., 2008]. Research into this complex continues to clarify the diversity of lipid signaling and the potential for tissue-specific drug design [Woodward et al., 2012].

Other names

Prostamide receptorBimatoprost receptorFP-altFP complexPTGFR-altPTGFR heterodimerPutative prostamide-sensitive FP complex

Agonism of the heterodimeric receptor complex leads to increased uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.